Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

METTL14-Mediated Bim mRNA m6A Modification Augments Osimertinib Sensitivity in EGFR-Mutant NSCLC Cells.

Molecular cancer research : MCR - 1 Nov 2024

Fan Siwen, Lv Xinwu, Zhang Chuantao, Zeng Bingbing, Liang Yanqing, Chen Danyang, Xu Zumin, Li Pan, Wu Shanshan, Liu Hao, Luo Kai, Liu Zongcai, Yi Yanmei

Abstract excerpt

Resistance to osimertinib represents a significant challenge for the successful treatment of non-small cell lung cancer (NSCLC) harboring activating mutations in EGFR. N6-methyladenosine (m6A) on mRNAs is critical for various biological processes, yet whether m6A regulates osimertinib resistance of NSCLC remains unknown. In this study, we demonstrated that developing osimertinib-resistant phenotypes depends on...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acrylamides
Share to Adenosine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Aniline Compounds

Share to Bcl-2-Like Protein 11

Share to Drug Resistance, Neoplasm

Share to Indoles

Share to Methyltransferases

Share to Pyrimidines

Source

Identifiers

PMID: 38953880
DOI: 10.1158/1541-7786.MCR-23-1018

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

METTL14-Mediated Bim mRNA m6A Modification Augments Osimertinib Sensitivity in EGFR-Mutant NSCLC Cells.PMID 38953880Read ↗

Methyltransferase like 7B is a potential therapeutic target for reversing EGFR-TKIs resistance in lung adenocarcinoma.Semantic proximity Read ↗

Lnc-TMEM132D-AS1 as a potential therapeutic target for acquired resistance to osimertinib in non-small-cell lung cancerSemantic proximity Read ↗

Lnc-TMEM132D-AS1 Confers Acquired Resistance to Osimertinib in Non-Small-Cell Lung CancerSemantic proximity Read ↗

The role of m6A methylation in targeted therapy resistance in lung cancerSemantic proximity Read ↗

M6A Methylation Regulators METTL3 and ALKBH5 are Risk Factors for EGFR-Mutant NSCLCSemantic proximity Read ↗

The histone-modified landscape: Core mechanisms of osimertinib resistance in EGFR-mutant lung cancer.Semantic proximity Read ↗

Exosomal long non-coding RNA MSTRG.292666.16 is associated with osimertinib (AZD9291) resistance in non-small cell lung cancerSemantic proximity Read ↗

MDM2 drives resistance to Osimertinib by contextually disrupting FBW7-mediated destruction of MCL-1 protein in EGFR mutant NSCLC.Semantic proximity Read ↗

Overcoming acquired resistance of epidermal growth factor receptor-mutant non-small cell lung cancer cells to osimertinib by combining osimertinib with the histone deacetylase inhibitor panobinostat (LBH589).Semantic proximity Read ↗

Loss of KMT5C Promotes EGFR Inhibitor Resistance in NSCLC via LINC01510-Mediated Upregulation of MET.Semantic proximity Read ↗

[Identification of SORD as A Key Gene Mediating Osimertinib Primary Resistance in EGFR-Mutant Lung Adenocarcinoma via Machine Learning and Methylomics].Semantic proximity Read ↗

Exosomal microRNAs as potential biomarkers for osimertinib resistance of non-small cell lung cancer patientsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.